New approaches and consequences for elderly cancer patients with focus on melanoma

Rob Roel Henry van den Brom

    Research output: ThesisThesis fully internal (DIV)

    602 Downloads (Pure)

    Abstract

    - We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients.
    - The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly.
    - The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients.
    - A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders.
    - Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.
    Original languageEnglish
    QualificationDoctor of Philosophy
    Awarding Institution
    • University of Groningen
    Supervisors/Advisors
    • Hospers, Geke, Supervisor
    • de Vries, Liesbeth, Supervisor
    • Schroder, Carolien, Co-supervisor
    • Haanen, John B. A. G., Assessment committee, External person
    • Nijman, Hans, Assessment committee
    • Kallenberg, Cees G. M., Assessment committee
    Award date25-Sep-2017
    Place of Publication[Groningen]
    Publisher
    Print ISBNs978-94-034-0081-5
    Electronic ISBNs978-94-034-0080-8
    Publication statusPublished - 2017

    Cite this